Jellyfish sting nearly 100 beachgoers in Daytona Beach over holiday weekend
Nearly 100 people were stung by jellyfish during Memorial Day weekend in Daytona Beach.
Officials urge caution but say most stings are minor and treatable on-site.
Despite warnings, beachgoers largely stayed in the water to enjoy the holiday.
DAYTONA BEACH, Fla. - Nearly 100 people were stung by jellyfish along Daytona Beach over the Memorial Day weekend, prompting warnings from local officials and beach safety crews.
What we know
Over Memorial Day weekend, 99 people were stung by jellyfish along Daytona Beach, according to Volusia County Beach Safety officials. The majority of stings were mild, though some individuals required hospital treatment. Jellyfish were spotted both in the surf and along the sand. Beach crews are responding by treating stings with vinegar and advising caution.
What we don't know
Officials have not identified the specific species of jellyfish responsible for the stings, nor have they indicated whether this sudden surge is tied to seasonal patterns or unusual ocean conditions. It also remains unclear whether more stings may occur in the coming days, or if additional safety measures will be implemented.
The backstory
Daytona Beach is a popular Memorial Day destination, often drawing large crowds. In past years, beach safety teams have responded to hundreds of water rescues during this weekend. While rescues dropped to 35 this year, jellyfish stings emerged as a new concern, shifting the focus of beach safety efforts.
The stings highlight the unpredictable nature of beach safety hazards. While rip currents typically dominate safety advisories, marine life can present unexpected risks—even on high-traffic weekends like Memorial Day. Yellow flags remain in place, alerting visitors to moderate water risks.
What they're saying
Volusia County Beach Safety Deputy Chief AJ Miller said beachgoers should stay alert but not overly alarmed.
"We've pulled out 35 people yesterday and Saturday from the water," he said. "We have jellyfish in the area. Just between Saturday and Sunday, we had 99 people stung by jellyfish."
Deputy Miller said it's important to pay attention.
"You can see them if you're really watching," Miller said, "But then you're going to spend your whole day staring at the water and not enjoying the day."
"It's a minor concern," said Brian Thatcher, a Jacksonville resident. "Everybody's trying to have a good time, go back to work tomorrow, so you got to do something to enjoy."
What you can do
Visitors are encouraged to seek help from lifeguards if stung; vinegar is available for treatment at beach stations. Those with allergies to insect stings are urged to be especially cautious, as they may be more sensitive to jellyfish venom. Despite the stings, most beachgoers were undeterred, soaking up the sun and surf before heading back to work.
STAY CONNECTED WITH FOX 35 ORLANDO:
Download the FOX Local app for breaking news alerts, the latest news headlines
Download the FOX 35 Storm Team Weather app for weather alerts & radar
Sign up for FOX 35's daily newsletter for the latest morning headlines
FOX Local:Stream FOX 35 newscasts, FOX 35 News+, Central Florida Eats on your smart TV
The Source
This story was written based on information shared by Volusia County Beach Safety, the Florida Fish and Wildlife Conservation Commission, and visitors to Daytona Beach on May 26, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Jim Cramer Says He 'Was Discouraged to Get a Mixed Update from Abbott Labs'
Abbott Laboratories (NYSE:ABT) is one of the stocks that Jim Cramer shed light on. Commenting on the company's recent earnings report results, Cramer said: 'Today, in an otherwise positive market, I was discouraged to get a mixed update from Abbott Labs, medical technology company that we've long owned for the Charitable Trust… I'd say two decades. When Abbott Labs reported this morning, the… results were perfectly solid. Management tightened their full-year earnings guidance rather than raising it while also taking down their organic sales growth forecast and their operating margin outlook. wavebreakmedia/ Abbott (NYSE:ABT) is a healthcare company engaged in the research, development, manufacture, and marketing of a wide range of medical products. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
18 minutes ago
- Yahoo
Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition
Eli Lilly and Company (NYSE:LLY) is one of the . Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company (NYSE:LLY) is a research-driven pharmaceutical leader headquartered in Indiana. With a 150-year history, the company carries on the business of discovering, developing, manufacturing, and marketing innovative treatments across diseases like diabetes and in fields like oncology, immunology, and neuroscience. Some of the company's notable products, such as Humalog, Trulicity, Mounjaro, and Zepbound, are marketed in over 125 countries. The company is carrying on multiple studies and its latest updates include the Phase 2b clinical study titled 'A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa' and Phase 3 clinical study titled 'A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ LY3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on a Background Therapy With Intranasal Corticosteroids.' Along with these studies, the company has a pipeline with potential drugs capable of generating more than $1 billion in annual revenue. Amid these studies, the company has agreed to buy Verve Therapeutics Inc. for up to $1.3 billion. With this acquisition, Eli Lilly and Company (NYSE:LLY) aims to strengthen its positions in gene editing for cardiovascular conditions. With a beta of 0.44 signaling the company's resistance to market conditions, Eli Lilly and Company (NYSE:LLY) has a high anticipated 5-year EPS growth of 41.87%, making the stock a strong contender in our list. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None.
Yahoo
18 minutes ago
- Yahoo
Vektor Medical's vMap Surpasses 2,000 Procedures, Driving a New Standard in Arrhythmia Care
Milestone Highlights Rapid Hospital Adoption and Clinical Demand for Arrhythmia Insights that Improve Outcomes and Reduce Procedure Time SAN DIEGO, July 23, 2025--(BUSINESS WIRE)--Vektor Medical today announced its vMap® system has been used in more than 2,000 procedures in the U.S., a milestone that underscores its rapid adoption by electrophysiologists (EPs) and hospitals seeking to improve procedural efficiency, reduce repeat interventions, and deliver better patient outcomes. vMap, developed with AI and designed to localize both focal and fibrillation-type arrhythmias, delivers actionable insights in all four chambers of the heart in less than a minute. Clinical studies have shown that use of vMap is associated with a reduction in procedure time, which may reduce fluoroscopy time and improve safety. vMap integrates seamlessly into existing systems, making it an increasingly valuable solution for electrophysiologists seeking greater efficiency and performance without compromise. vMap is now in use at over 20 hospitals throughout the United States. "vMap has become an integral part of how I care for patients," said Dr. Anish Amin, Section Chief, Electrophysiology, OhioHealth Heart and Vascular. "It's efficient, non-invasive, and delivers insights that enhance every stage of the ablation process from planning through execution. With vMap, I can pinpoint arrhythmia sources faster with greater confidence, treat more accurately, and potentially reduce repeat interventions for patients. I'm looking forward to enrolling patients in the IMPRoVED-AF study, which will further validate the clinical impact of this technology and its potential to transform how we approach AF ablation." As adoption of pulsed field ablation (PFA) accelerates, the need for accurate, accessible data is greater than ever. vMap can enhance the impact of PFA by helping EPs identify optimal ablation targets before entering the lab and reiteratively during the procedure. With vMap's rapid, non-invasive ECG-based driver localization, physicians have more information to better target areas of interest, supporting more efficient procedures and unlocking the full potential of PFA. "This milestone represents meaningful momentum," said Robert Krummen, CEO of Vektor Medical. "With every procedure, physicians are leveraging vMap's rapid, non-invasive insights to make informed decisions and streamline care. We're seeing growing demand quarter over quarter as both physicians and hospitals look for ways to enhance efficiency and elevate patient care." The vMap system is FDA-cleared and commercially available in the United States. As clinical use continues to expand, Vektor Medical remains focused on advancing the future of arrhythmia care through clinical innovation, strategic partnerships, and physician impact. To learn more about Vektor Medical, vMap technology, or to request a clinical or strategic briefing, visit and connect with us on LinkedIn and X. About Vektor Medical Headquartered in San Diego, Vektor Medical is redefining how arrhythmias are understood and treated. The company developed vMap®, the only FDA-cleared, non-invasive technology that uses standard 12-lead ECG data to localize arrhythmia source locations across all four chambers of the heart. By helping physicians identify arrhythmia drivers more quickly and with greater accuracy, Vektor is improving outcomes, enhancing efficiencies, and accelerating access to effective treatment strategies. To learn more, visit View source version on Contacts Media Contact Stacey HolifieldLevitate(617) 233-3873vektor@
